Key result
Biomarkers such as Ang-II, TGF-beta, ET-1, and IL-6 are implicated in corticosteroid-induced hypertrophic cardiomyopathy in preterm infants, potentially converging on increased intracellular calcium.
Systematic Review
This review outlines the pathophysiological roles of various biomarkers in corticosteroid-induced hypertrophic cardiomyopathy in preterm infants, suggesting potential diagnostic and therapeutic targets.
May inform biomarker monitoring in corticosteroid-treated preterm infants; extends mechanistic data and leaves open targeted trials.
The study of biomarkers and their signaling pathways has led to the development of new therapeutic strategies in a number of disorders. The purpose of the present systematic review is to provide an overview of different biomarkers in preterm newborns with corticosteroid-induced hypertrophic cardiomyopathy (CCHC). Several pathophysiological biomarkers are presented and discussed with the aim of investigating their diagnostic and prognostic value, particularly in relation to the potential progression of the disease and/or mortality in adulthood. This investigative approach may not only provide pathophysiological information on this serious drug-induced adverse effect, but also suggest novel therapeutic approaches to be applied in controlling its harmful consequences.
No takes yet. Share an insight, caveat, or question.
Pier Paolo Bassareo (2010) conducted a systematic review in Corticosteroid-induced hypertrophic cardiomyopathy. Corticosteroids was evaluated. Biomarkers such as Ang-II, TGF-beta, ET-1, and IL-6 are implicated in corticosteroid-induced hypertrophic cardiomyopathy in preterm infants, potentially converging on increased intracellular calcium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: